You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 8,808,737

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,808,737 protect, and when does it expire?

Patent 8,808,737 protects OPANA ER and is included in two NDAs.

Summary for Patent: 8,808,737

Title:	Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Abstract:	The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
Inventor(s):	Ahdieh; Harry (Lincoln University, PA)
Assignee:	Endo Pharmaceuticals Inc. (Malvern, PA)
Application Number:	12/716,973
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,808,737
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,808,737

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-001	Jun 22, 2006		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				DOSE MODIFICATION FOR RENAL IMPAIRMENT	⤷ Try a Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE	⤷ Try a Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-005	Feb 29, 2008		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				DOSE MODIFICATION FOR RENAL IMPAIRMENT	⤷ Try a Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-002	Dec 9, 2011		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE	⤷ Try a Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-002	Jun 22, 2006		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				DOSE MODIFICATION FOR RENAL IMPAIRMENT	⤷ Try a Trial
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.